News

Dimension Therapeutics is focused on developing new adeno-associated virus (AAV) gene therapy treatments for rare diseases. Bayer HealthCare member of the Executive Committee and head of Global Drug

Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a deal with Curis, a US-based oncology-focused biotechnology firm. Curis president and chief executive

The expansion will add 50 patients to the original cohort of 56 patients to produce more robust results. The trial is enrolling non-metastatic prostate cancer patients who have

"We are very pleased to establish this strategic collaboration with TD2, as we see significant synergies between Inform Genomics’ proprietary technology and analytics along with TD2’s world-class oncology

miRagen and Servier Research will continue preclinical research and development on multiple cardiovascular programs targeting microRNAs, including miR-208 and miR-15. Servier will lead the global clinical development and

The dispensary is a well-known, high volume dispensary licensed in medical and recreational marijuana sales. The 100-day pilot program is designed to test for compliance and tracking integration

BL-1110 may also be developed for the treatment of scleroderma, an autoimmune disease characterized by a hardening and tightening of the skin and connective tissues. The compound, which

The open-label trial (HPV-004) is designed to assess safety, immunogenicity, clinical responses and disease-free survival of INO-3112 in female patients with inoperable invasive cervical cancer. INO-3112 is a

The partnership will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands. BIND Therapeutics chief executive officer Scott Minick said the addition of